Safety in numbers: risankizumab for moderate-to-severe psoriasis. Mirali S, Fabusiwa K, Linos E. Br J Dermatol 2022 Feb 20. doi: 10.1111/bjd.20947.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mirali S, Fabusiwa K, Linos E. Safety in numbers: risankizumab for moderate-to-severe psoriasis. Br J Dermatol 2022 Feb 20. doi: 10.1111/bjd.20947.
PMID: 35187640